Table 3.
Phase 3 trials of checkpoint inhibitors plus chemotherapy for first line treatment of metastatic squamous NSCLC.
| Trial | PD-L1 staining* | Therapy | ORR (95% CI) | Median PFS (95% CI) | Median OS (95% CI) | 1 year OS (95% CI) |
|---|---|---|---|---|---|---|
| KEYNOTE-407 (23, 24) | TC ≥ 50% | Pembrolizumab + Carboplatin + Paclitaxel or Nab-Paclitaxel (n = 103) | 60.3% (48.1–71.5) | 8.0 mo (6.1–10.3) | NR (11.3-NE) | 63.4%a |
| Carboplatin + Paclitaxel or Nab-Paclitaxel (n = 104) | 32.9% (22.3–44.9) | 4.2 mo (2.8–4.6) | NR (7.4-NE) | 51.0%a | ||
| Any | Pembrolizumab + Carboplatin + Paclitaxel or Nab-Paclitaxel (n = 278) | 57.9% (51.9–63.8) | 6.4 mo (6.2–8.3) | 15.9 mo (13.2-NR) | 65.2%a | |
| Carboplatin + Paclitaxel or Nab-Paclitaxel (n = 281) | 38.4% (32.7–44.4) | 4.8 mo (4.3–5.7) | 11.3 mo (9.5–14.8) | 48.3%a | ||
| IMpower131 (25) | TC ≥ 50% or IC ≥ 10%b | Atezolizumab + Carboplatin + Nab-paclitaxel (n = 53) | 60%a | 10.1 moa | 23.6 moa | N/A |
| Carboplatin + Nab-paclitaxel (n = 48) | 33%a | 5.5 moa | 14.1moa | N/A | ||
| Any | Atezolizumab + Carboplatin + Nab-paclitaxel (n = 343) | 49%a | 6.3 mo (5.7–7.1) | 14.0 mo (12.0–17.0) | N/A | |
| Carboplatin + Nab-paclitaxel (n = 340) | 41%a | 5.6 mo (5.5–5.7) | 13.9 mo (12.3–16.4) | N/A |
*
PD-L1 staining on tumor cells was defined by the 22C3 assay for pembrolizumab. With atezolizumab PD-L1 staining on tumor cells or immune cells was done using the SP142 assay. Platinum includes either carboplatin or cisplatin.
a
Confidence interval not available.
b
For the IMpower131 study patients with PD-L1 ≥50% on tumor cells or PD-L1 ≥10% immune cells are grouped together as PD-L1 high.
PD-L1, programmed death ligand 1; ORR, objective response rate; PFS, progression free survival; OS, overall survival; CI, confidence interval; mo, months; NR, not reached; NE, not evaluable; TC, tumor cells; IC, immune cells; N/A, not available.